MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer

作者：Ming‐Sound Tsao, Lynette Marie Sholl, Michelle Shiller, Peter Bela Illei, Ignacio Ivan Wistuba, Mary Beth Beasley, Kurt Alex Schalper, Archana R. Simmons, Peter J. Ansell, Sue Beruti, Mari A. Mino-Kenudson · 发表于：npj Precision Oncology · 年份：2025 · DOI：10.1038/s41698-025-01144-9 · 被引用次数：11 · 研究领域：Liver physiology and pathology、Lung Cancer Treatments and Mutations、Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

MET protein (also known as c-Met protein) overexpression (OE) is an emerging clinically relevant biomarker that is targetable with antibody-drug conjugates. c-Met protein's prevalence varies, depending on the different OE thresholds, antibodies, and detection methodologies used. Unlike MET genomic aberrations, MET protein OE is a protein biomarker requiring immunohistochemistry (IHC)-based testing. Herein, we summarize the current evidence on MET protein OE, including prognostic value, heterogeneity, and stability. We also provide key considerations for enabling optimal real-world testing of this IHC-based biomarker.